Malaysia , 04-December-2025 — The Malaysian Medical Device Authority (MDA) is set to roll out a critical update to its regulatory framework, one that could significantly streamline compliance for local and international manufacturers. The new draft of Guidance Document MDA/GD/0006, which defines what qualifies as a “Medical Device,” offers much-needed clarity on how to treat accessories, components, and spare parts. For medical device manufacturers, this guidance is a game-changer, as it directly impacts what needs separate, costly registration and what is covered under a simpler process.
THE NEW MDA REGULATORY GUIDANCE BREAKDOWN: REGISTRATION REQUIRED VS. QMS CONTROL
The core impact of this updated guidance is in drawing sharp, regulatory lines between the different pieces that make up your medical product. Manufacturers must understand these distinctions to avoid registration delays or compliance pitfalls.
Device Part | The Definition | The Regulatory Impact (Manufacturer’s Action) |
Accessory | An item specifically intended by the manufacturer to be used with a main medical device, either to enable its purpose or to extend its capabilities. | FULL REGISTRATION REQUIRED. Accessories are regulated as a medical device in their own right. This means you must classify and register each accessory separately. |
Component | A built-in, essential mechanical, electrical, electronic, or software element that is integrated during the initial manufacturing phase to make the device work. | NO SEPARATE REGISTRATION. A component is not considered a medical device. Its safety and quality are controlled solely through the manufacturer’s established Quality Management System (QMS) and the conformity assessment for the main device. |
Spare Part | A replacement item sold separately to repair or maintain a medical device after it has already been placed on the market. | NO REGISTRATION REQUIRED. Spare parts are explicitly not classified as medical devices and do not require approval for importation, exportation, or market placement under Act 737. |
HOW WILL THE NEW MDA REGULATORY GUIDELINES AFFECT MANUFACTURERS
This clarification is a significant relief, particularly for the post-market phase of a product’s life cycle.
- Simplified After-Sales Support: The explicit exemption of spare parts from registration removes a major administrative hurdle. Supplying simple replacement items like a battery pack for a defibrillator or a display screen for a patient monitor is now faster and simpler, provided they are identical to the original approved components and don’t affect the device’s safety or performance.
- Clearer Manufacturing Oversight: By distinguishing non-medical device components and placing their control firmly within the manufacturer’s QMS (such as ISO 13485), the guidance eliminates unnecessary red tape for built-in, non-standalone parts. This allows manufacturers to manage their internal parts inventory and changes with more flexibility.
The MDA is providing the industry with a clear map: if your product or part performs a medical function on its own (an Accessory), register it. If it’s a piece you put inside the device (a Component) or a simple replacement part (a Spare Part), manage it through your QMS, saving time and resources on regulatory submissions. This guidance is currently open for public comment until December 18, 2025. Manufacturers are encouraged to review the full document and provide feedback to ensure the final version supports both public safety and industry growth.